desmopressin + tolterodine

**Desmopressin + tolterodine** is a combination of two small-molecule drugs used primarily to treat nocturnal enuresis (bedwetting) and nocturia, especially in patients with overactive bladder (OAB)[1][2][3]. **Desmopressin** is a synthetic analogue of vasopressin, acting as a selective agonist at the vasopressin V2 receptor, promoting renal water reabsorption and reducing urine production at night. **Tolterodine** is an antimuscarinic agent that acts as a competitive antagonist at muscarinic acetylcholine receptors (mainly the M2 and M3 subtypes) in the bladder, reducing detrusor overactivity and bladder muscle contractions. Combination therapy demonstrates superior efficacy in reducing nocturnal voids and improving response rates compared to monotherapy with either agent, particularly in nocturnal enuresis in children and nocturia associated with OAB in adults[1][2][3]. The safety profile of the combination is favorable, with a low incidence of significant side effects. No unique brand name for this fixed combination is identified; it is used as a co-administered regimen.